TEL AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, will present new data for Metadoxine Extended Release (MDX or MG01CI) at the upcoming 167th Annual Meeting of the American Psychiatric Association (APA) and 69th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), both held in New York, NY. Details of the presentations are as follows:
Help employers find you! Check out all the jobs and post your resume.
